From December 2025 – February, 2026, AmeriPharma Infusion Center compiled pricing data from Medicare reimbursement schedules, pharmaceutical databases, and insurance fee schedules to provide patients with a comprehensive overview of Gammagard infusion costs. This report analyzes the key cost factors affecting Gammagard therapy, including medication pricing, administration fees, insurance coverage variations, and available financial assistance programs. Our analysis reveals that while Gammagard remains one of the more expensive IVIG therapies, strategic use of copay assistance programs and choosing the right infusion setting can reduce out-of-pocket costs by 70-100% for eligible patients.
Gammagard Liquid Pricing by Dosage (2026)
The base cost of Gammagard Liquid varies significantly based on the volume prescribed. Gammagard is dosed by body weight, typically at 300-600 mg/kg every 3-4 weeks for primary immunodeficiency conditions. The table below shows average wholesale pricing for different vial sizes:
| Vial Size | Price Per Vial | Price Per mL | Typical Patient Use |
| 10 mL (1g) | $178.46 | $17.85 | Pediatric/Low-dose |
| 25 mL (2.5g) | $434.31 | $17.37 | Small adult dose |
| 50 mL (5g) | $860.70 | $17.21 | Medium adult dose |
| 100 mL (10g) | $1,713.49 | $17.13 | Large adult dose |
| 200 mL (20g) | $3,419.08 | $17.10 | High-dose therapy |
| 300 mL (30g) | $5,124.67 | $17.08 | Maximum single infusion |
Source: Drugs.com Pharmaceutical Pricing Database, January 2026
For context, a 70 kg (154 lb) adult receiving a standard 400 mg/kg dose would require 28 grams of Gammagard Liquid per infusion, translating to approximately $4,782 in medication costs alone before insurance coverage or copay assistance.
Complete Treatment Cost Breakdown: Medication + Administration
The total cost of Gammagard infusion therapy extends beyond the medication itself. Patients must consider administration fees, which vary dramatically based on the care setting:
| Cost Component | Hospital Outpatient | Standalone Infusion Center | Home Infusion |
| Gammagard Liquid (28g dose) | $4,782-$7,200 | $4,782-$5,500 | $4,782-$5,200 |
| Infusion Administration Fee | $1,500-$3,000 | $400-$800 | $350-$600 |
| Facility/Room Fee | $800-$2,500 | $0-$200 | $0 |
| Nursing/Monitoring | Included in admin fee | Included in admin fee | $150-$300 |
| Supplies (IV line, pump, etc.) | $200-$400 | $100-$200 | $100-$250 |
| Total Per Infusion | $7,282-$13,100 | $5,282-$6,700 | $5,382-$6,350 |
| Annual Cost (13 treatments) | $94,666-$170,300 | $68,666-$87,100 | $69,966-$82,550 |
Source: AmeriPharma Infusion Center Insurance Verification Data, January 2026; National Home Infusion Association Cost Analysis, 2025
Hospital outpatient departments consistently charge 3-5 times more than standalone infusion centers for the same therapy. AmeriPharma Infusion Center’s transparent pricing model falls within the standalone infusion center range, offering patients substantial savings compared to hospital-based care. Additionally, patients receiving infusions at hospitals face higher risk of exposure to other illnesses in crowded waiting areas — an important consideration when managing immunodeficiency conditions.
Medicare and Insurance Coverage for Gammagard
Insurance coverage significantly impacts patient out-of-pocket costs. Gammagard is typically covered under Medicare Part B (for medical conditions) rather than Part D (prescription drugs), since it’s administered by healthcare professionals.
Medicare 2026 Coverage Details
| Coverage Element | 2026 Details | Patient Responsibility |
| Medicare Part B Premium | $202.90/month (standard) | Monthly payment required |
| Annual Deductible | $283 | Pay first $283 of costs |
| Coinsurance After Deductible | 20% of approved amount | 20% of total treatment cost |
| Gammagard Reimbursement Rate (per 500mg) | $47.29 (code J1569) | N/A |
| Typical Annual Out-of-Pocket (before assistance) | $9,200 -$18,400 | Varies by frequency |
| Medicare Advantage Out-of-Pocket Maximum (In-Network) Medicare Advantage Out-of-Pocket Maximum (Out-of-Network) | Up to $9,250 (in-network) Up to $14,000 (out-of-network) | Maximum annual exposure |
Source: Centers for Medicare & Medicaid Services, Medicare Part B Fee Schedule, January 2026; GoodRx Medicare Coverage Analysis, 2025
For a patient receiving monthly infusions at $6,000 per treatment (medication + administration), annual costs would reach $72,000. After Medicare covers 80%, the patient’s 20% coinsurance would total $14,400 annually — a substantial burden that copay assistance programs are designed to address.
Private Insurance Cost Variations
Private insurance coverage for Gammagard varies widely by plan type and carrier. Our analysis of major insurance providers reveals:
| Insurance Type | Typical Coverage % | Annual Deductible | Out-of-Pocket Maximum | Estimated Annual Patient Cost |
| PPO Plans | 70-90% after deductible | $2,000-$5,000 | $8,000-$10,000 | $8,000-$10,000 |
| HMO Plans | 80-90% after deductible | $1,500-$3,000 | $6,000-$8,000 | $6,000-$8,000 |
| High-Deductible Health Plans | 80% after deductible | $3,000-$7,000 | $7,000-$14,000 | $7,000-$14,000 |
| Medicaid/Medi-Cal | 90-100% | $0-$500 | $0-$2,000 | $0-$2,000 |
| Medicare Advantage | 80-90% after deductible | $0-$500 | Up to $9,350 | $2,000-$9,350 |
Source: Kaiser Family Foundation Health Insurance Survey, 2025; AmeriPharma Infusion Center Insurance Verification Data, January 2026
Patients with high-deductible health plans face the highest initial costs but may qualify for more generous copay assistance programs. AmeriPharma Infusion Center’s in-house insurance verification team proactively contacts insurers to confirm coverage, benefits, and out-of-pocket costs before treatment begins. Our team of insurance specialists handles this process day in and day out — they have the knowledge to navigate complex insurance guidelines and understand what details insurance companies are looking for in order to deem the treatment medically necessary and secure your insurance approvals.
Gammagard Copay Assistance Programs (2026)
Multiple financial assistance programs exist specifically for Gammagard patients. These programs can reduce out-of-pocket costs to zero for eligible patients:
| Program Name | Eligibility | Maximum Annual Benefit | Covers | Application Process |
| Takeda Patient Support Co-Pay Assistance | Commercially insured patients | Up to $20,000/year (100% of copay) | Copays, coinsurance, deductibles | Phone: 866-861-1750 or online |
| Patient Access Network (PAN) Foundation | Income 400-500% of FPL, insured | Varies by fund availability | Copays, deductibles | Online application required |
| HealthWell Foundation | Varies by condition, insured | Varies by fund availability | Copays, premiums, deductibles | Phone: 800-675-8416 |
| Takeda Patient Assistance Program | Uninsured/underinsured, income-based | Free medication | Gammagard medication only | Income verification required |
Source: Takeda Pharmaceuticals Patient Support Programs, January 2026; Drugs.com Patient Assistance Directory, 2025
AmeriPharma Infusion Center has secured over $55 million in financial assistance for patients across all our service lines. Our dedicated Copay Assistance Specialists work with patients to identify the right funding programs and guide them through the application process. In many cases, eligible patients qualify for zero out-of-pocket expenses.
Cost Factors That Affect Your Gammagard Treatment
Several variables influence the final cost of Gammagard therapy:
| Cost Factor | Impact on Total Cost | Patient Control | Cost Optimization Strategy |
| Body Weight | +$170 per 10 kg increase | None | Ensure accurate dosing calculations; some protocols use ideal body weight for obese patients |
| Dosage Frequency | 12 vs. 13 treatments/year = $6,000+ difference | Limited | Work with physician on optimal dosing schedule |
| Infusion Site | Hospital vs. center = $25,000-$80,000/year | High | Choose standalone infusion centers like AmeriPharma |
| Insurance Type | Varies by $2,000-$12,000/year | Moderate | Review during open enrollment; compare formularies |
| Copay Assistance Enrollment | Can eliminate $8,000-$20,000/year | High | Apply to all eligible programs early in calendar year |
| Insurance Approval Process | Delays can cause treatment gaps | Moderate | Choose providers with dedicated insurance approval support teams |
Source: AmeriPharma Infusion Center Insurance Verification Data, January 2026
The single most impactful decision patients can make is selecting their infusion location. Data from the American Journal of Managed Care shows that hospital-based IVIG costs average $29,164 annually compared to $22,211 for home-based or outpatient center infusions — a difference of nearly $7,000 per year.
Why Gammagard Costs Vary Between Patients
Even patients with the same diagnosis and similar weight can experience vastly different costs. Our analysis identified five primary reasons:
1. Insurance Formulary Tier Placement: Some insurance plans classify Gammagard as a preferred specialty medication (Tier 3) while others place it in non-preferred specialty (Tier 4 or 5), doubling or tripling copay amounts.
2. In-Network vs. Out-of-Network Status: Patients receiving Gammagard at out-of-network facilities may pay 40-60% of costs instead of 10-20% at in-network providers. All AmeriPharma Infusion Center locations accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances.
3. Annual Reset Timing: Patients who begin therapy late in the calendar year may face two deductible cycles within months, while those starting in January spread costs throughout the year.
4. Copay Assistance Awareness: Many patients remain unaware of available assistance programs. AmeriPharma data shows that only 60% of eligible patients initially apply for copay assistance without guidance from specialized teams.
5. Site-of-Care Economics: Hospital billing structures include facility fees and departmental overhead that standalone infusion centers avoid, leading to the 3-5x cost differential noted earlier.
Reducing Your Gammagard Infusion Costs: Actionable Steps
Based on our research and experience serving thousands of infusion patients, we recommend these strategies:
Choose a Specialized Infusion Center: Standalone infusion centers like AmeriPharma offer the same clinical expertise and IgCN-certified nursing staff as hospitals but at a fraction of the cost. Our state-of-the-art facilities provide comfortable, convenient alternatives to hospital-based care.
Apply for Copay Assistance Early: The Takeda Patient Support Co-Pay Assistance Program can cover up to 100% of out-of-pocket costs for commercially insured patients. Apply at the beginning of your calendar year to maximize benefits.
Verify Insurance Coverage Proactively: AmeriPharma’s in-house billing and insurance verification teams contact insurers before your first infusion to confirm coverage, copays, and whether insurance approvals are needed. Our team pre-screens chart notes and supporting documentation to determine if additional details are required to give your case the best possible approval rate — eliminating surprise bills and securing approvals when other pharmacies fail.
Compare Annual Out-of-Pocket Maximums During Open Enrollment: If your current plan has a $10,000 out-of-pocket maximum but an alternative offers $6,000, the switch could save $4,000 annually.
Explore Medicare Prescription Payment Plan: Starting in 2025, Medicare Part B beneficiaries can spread costs throughout the year instead of paying upfront, making budgeting more manageable.
The AmeriPharma Approach to Transparent Gammagard Pricing
At AmeriPharma Infusion Center, we believe patients shouldn’t face financial stress on top of managing chronic conditions. Our approach includes:
- Upfront Cost Estimates: Before your first infusion, we provide clear estimates of your total costs, including insurance coverage and potential copay assistance.
- Dedicated Financial Navigators: Our Copay Assistance Specialists have secured over $55 million in financial assistance, with some patients qualifying for zero out-of-pocket expenses.
- Transparent Pricing: We charge competitive rates aligned with standalone infusion center benchmarks — not hospital premium pricing.
- Insurance Coordination: Our billing team handles insurance approvals, copay assistance applications, and works proactively with your physician to ensure all necessary documentation is complete before submitting. We forewarn prescribers when a case needs additional supporting information, reducing the administrative burden on patients and families.
Gammagard infusion therapy is a critical treatment for primary immunodeficiency, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. While costs are substantial, strategic planning and proactive enrollment in assistance programs can make this life-changing therapy accessible and affordable.
How AmeriPharma Infusion Center Supports Your Gammagard Treatment
If you’ve been prescribed Gammagard therapy and are concerned about costs, AmeriPharma Infusion Center offers comprehensive support throughout your treatment journey. All our locations provide:
- IgCN-Certified Infusion Nurses: Specialized training in immunoglobulin therapy administration
- Comfortable Infusion Suites: Resort-style amenities at our Orange and Beverly Hills locations; all locations offer comfortable, state-of-the-art infusion spaces
- 24/7/365 Support: Access to clinical pharmacists and nursing support around the clock
- Comprehensive Insurance Navigation: From insurance approvals to copay assistance enrollment
- Accredited Care: NABP, ACHC, URAC, and LegitScript certified facilities
Our team understands that managing insurance approvals and securing financial aid can be overwhelming when you’re already dealing with a chronic condition. We’re here to help make the process as stress-free as possible.
If you’d like to request a cost estimate for Gammagard infusion therapy or learn more about financial assistance options, you can reach out here.
REFERENCES:
- Drugs.com Pharmaceutical Pricing Database – “Gammagard Liquid Prices, Coupons, Copay Cards & Patient Assistance,” accessed January 2026
- Centers for Medicare & Medicaid Services – “Intravenous Immune Globulin Items & Services,” MLN Fact Sheet, January 2025
- GoodRx – “Gammagard Medicare Coverage and Co-Pay Details,” January 2025
- American Journal of Managed Care – “Managing Cost of Care and Healthcare Utilization in Patients Using Immunoglobulin Agents,” 2024
- National Home Infusion Association – “Cost Savings: Home Versus Inpatient Infusion Therapy,” 2025
- Kaiser Family Foundation – “Employer Health Benefits Annual Survey,” 2025
- Takeda Pharmaceuticals – “Gammagard Liquid Patient Support Programs,” January 2026











